公开(公告)号：US11897879B2

公开(公告)日：2024-02-13

申请号：US17528677

申请日：2021-11-17

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takaharu Hirayama ,  Yoshiteru Ito ,  Noriyuki Nii ,  Youichi Kawakita ,  Shinichi Imamura

IPC: C07D471/04 ,  C07D487/04

CPC classification number: C07D471/04 ,  C07D487/04

Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.

公开(公告)号：US20210332045A1

公开(公告)日：2021-10-28

申请号：US17367171

申请日：2021-07-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takaharu Hirayama ,  Yoshiteru Ito ,  Hiroshi Banno ,  Hidekazu Tokuhara ,  Toshio Tanaka ,  Yasuyoshi Arikawa ,  Noriyuki Nii ,  Youichi Kawakita ,  Shinichi Imamura

IPC: C07D471/04

Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.

公开(公告)号：US10800754B2

公开(公告)日：2020-10-13

申请号：US16332993

申请日：2017-09-14

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takaharu Hirayama ,  Yasuhiro Hirata ,  Yusuke Tominari ,  Naoki Iwamura ,  Yusuke Sasaki ,  Moriteru Asano ,  Terufumi Takagi ,  Masanori Okaniwa ,  Masato Yoshida ,  Shinichi Imamura

IPC: C07D401/04 ,  C07D401/14 ,  C07D407/14 ,  C07D409/14 ,  C07D417/14 ,  A61P35/00

Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US10676461B2

公开(公告)日：2020-06-09

申请号：US16342892

申请日：2017-10-17

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Katsunori Nagai ,  Takuto Kojima ,  Shinichi Imamura ,  Masao Hirakata

IPC: C07D401/14 ,  A61P3/00 ,  A61P35/00 ,  A61K9/00 ,  A61K31/05 ,  A61K31/09 ,  A61K31/57 ,  A61K31/58 ,  A61K31/6615 ,  A61P43/00 ,  A61K31/498 ,  A61K45/06

Abstract: The present invention relates to N-((3S,4R)-1-((8-chloroquinoxalin-6-yl)carbonyl)-3-(4-fluorophenyl)piperidin-4-yl)-1-methyl-5-(trifluoromethyl)-1H-pyrazole-3-carboxamide, which is a compound that can be useful for the treatment or prevention of SPT-related diseases including congenital diseases associated with the storage of sphingolipids, such as cancer and Niemann-Pick disease, or a salt thereof.

公开(公告)号：US20150266881A1

公开(公告)日：2015-09-24

申请号：US14435085

申请日：2013-10-11

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Naoki Tomita ,  Daisuke Tomita ,  Yusuke Tominari ,  Shinichi Imamura ,  Shinji Morimoto ,  Takuto Kojima ,  Masashi Toyofuku ,  Yasushi Hattori ,  Tomohiro Kaku ,  Mitsuhiro Ito

IPC: C07D487/04 ,  C07D231/38 ,  C07C237/38 ,  C07C237/30 ,  C07D241/12 ,  C07D213/36 ,  C07D471/04 ,  C07D207/46 ,  C07D241/18 ,  C07D319/18 ,  C07D265/36 ,  C07D333/20 ,  C07D285/135 ,  C07D277/38 ,  C07D405/12 ,  C07D417/12 ,  C07D413/12 ,  C07D223/12 ,  C07D513/04 ,  C07C237/40

CPC classification number: C07D487/04 ,  A61K45/06 ,  C07C237/30 ,  C07C237/38 ,  C07C237/40 ,  C07C255/29 ,  C07C255/58 ,  C07C255/60 ,  C07C317/40 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07D207/12 ,  C07D207/46 ,  C07D211/58 ,  C07D213/36 ,  C07D213/40 ,  C07D223/12 ,  C07D231/38 ,  C07D231/40 ,  C07D241/12 ,  C07D241/18 ,  C07D261/14 ,  C07D265/36 ,  C07D277/38 ,  C07D285/135 ,  C07D295/135 ,  C07D309/14 ,  C07D319/18 ,  C07D333/20 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D513/04

Abstract: The present invention provides a compound having a lysine specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's disease, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); B is a benzene ring optionally having further substituent(s); R1, R2 and R3 are each independently a hydrogen atom, a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); A and R1 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s); and R2 and R3 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s), or a salt thereof.

Abstract translation: 本发明提供了具有赖氨酸特异性脱甲基酶1抑制作用的化合物，可用作精神分裂症，阿尔茨海默病，帕金森病或亨廷顿病等预防或治疗药物等药物。 本发明涉及由下式表示的化合物：其中A是任选具有取代基的烃基或任选具有取代基的杂环基; B是任选具有其它取代基的苯环; R 1，R 2和R 3各自独立地为氢原子，任选具有取代基的烃基或任选具有取代基的杂环基; A和R1任选地彼此键合，与相邻的氮原子一起形成任选具有取代基的环状基团; R 2和R 3可以相互键合，与相邻的氮原子一起形成任选具有取代基的环状基团或其盐。